Drug · CHEMBL192
SILDENAFIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SILDENAFIL. Drugs and targets, record CHEMBL192. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL192
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 91 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | Phosphodiesterase 5A inhibitor | INHIBITOR | https://conductscience.org/library/genes/8654 |
Source ChEMBL
Diseases91
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| erectile dysfunction | Approval | ATC, EMA Human Drugs and TTD | 53 | 44 | https://conductscience.org/library/drugs?q=MONDO_0005362 |
| pulmonary hypertension | Approval | EMA Human Drugs | 36 | 33 | https://conductscience.org/library/drugs?q=MONDO_0005149 |
| pulmonary arterial hypertension | Phase 3 | ClinicalTrials.gov | 20 | 20 | https://conductscience.org/library/drugs?q=MONDO_0015924 |
| heart failure | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0005252 |
| idiopathic pulmonary fibrosis | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=EFO_0000768 |
| brain injury | Phase 2 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0043510 |
| persistent fetal circulation syndrome | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0022430 |
| Infertility | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0000789 |
| cystic fibrosis | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0009061 |
| fetal growth restriction | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005030 |
1 to 10 of 91Source Open Targets
See all 91 diseasesTrials335
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02060487 | Effects of Oral Sildenafil on Mortality in Adults With PAH | Phase 4 | 385 | 2022-05-10 | sildenafil | Its name | ClinicalTrials.gov |
| NCT01352507 | A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China | Phase 4 | 383 | 2013-04-26 | sildenafil | Its name | ClinicalTrials.gov |
| NCT00734604 | A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes. | Phase 3 | 378 | 2010-11-18 | sildenafil | Its name | ClinicalTrials.gov |
| NCT02802345 | Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment | Phase 3 | 274 | 2019-01-11 | sildenafil | Its name | ClinicalTrials.gov |
| NCT03364335 | The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity | Phase 2 | 267 | 2018-11-27 | sildenafil | Its name | ClinicalTrials.gov |
| NCT00159913 | A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension. | Phase 3 | 235 | 2009-07-21 | sildenafil | Its name | ClinicalTrials.gov |
| NCT02891850 | Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy | Phase 4 | 225 | 2021-01-22 | sildenafil | Its name | ClinicalTrials.gov |
| NCT00763867 | Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study) | Phase 3 | 216 | 2013-07-03 | sildenafil | Its name | ClinicalTrials.gov |
| NCT00301262 | Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied | Phase 4 | 183 | 2008-12-09 | sildenafil | Its name | ClinicalTrials.gov |
| NCT00517933 | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis | Phase 3 | 180 | 2013-08-23 | sildenafil | Its name | ClinicalTrials.gov |
1 to 10 of 335
See all 335 trialsComparisons in its trials61
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nintedanib+Placebo vs Nintedanib+Sildenafil: deaths from any cause | 12 of 136 | 12 of 137 | 273 | NCT02802345 | Trial comparisons |
| Nintedanib+Placebo vs Nintedanib+Sildenafil: serious adverse events | 44 of 136 | 37 of 137 | 273 | NCT02802345 | Trial comparisons |
| Riociguat vs PDE-5i: deaths from any cause | 0 of 111 | 4 of 114 | 225 | NCT02891850 | Trial comparisons |
| Riociguat vs PDE-5i: serious adverse events | 8 of 111 | 19 of 114 | 225 | NCT02891850 | Trial comparisons |
| Riociguat vs PDE-5i: Number of Participants With Adjudicated Clinical Worsening at Week 24 | 1 of 111 | 10 of 113 | 224 | NCT02891850 | Trial comparisons |
| Sildenafil vs Placebo: serious adverse events | 25 of 113 | 16 of 103 | 216 | NCT00763867 | Trial comparisons |
| Sildenafil vs Placebo: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) | 9 of 89 | 6 of 91 | 180 | NCT00517933 | Trial comparisons |
| Sildenafil vs Placebo: serious adverse events | 13 of 89 | 15 of 91 | 180 | NCT00517933 | Trial comparisons |
| Pirfenidone+Sildenafil vs Pirfenidone+Placebo: deaths from any cause | 28 of 88 | 36 of 89 | 177 | NCT02951429 | Trial comparisons |
| Pirfenidone+Sildenafil vs Pirfenidone+Placebo: serious adverse events | 54 of 88 | 55 of 89 | 177 | NCT02951429 | Trial comparisons |
1 to 10 of 61
See all 61 comparisons in its trialsPapers from its trials183
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL192
GET https://conductscience.org/api/drugs/v1/CHEMBL192/diseases?page=2